Daniele Generali
Affiliations: | 2003-2006 | University of Oxford, Oxford, United Kingdom |
Google:
"Daniele Generali"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Generali D, Berardi R, Caruso M, et al. (2023) Aromatase inhibitors: the journey from the state of the art to clinical open questions. Frontiers in Oncology. 13: 1249160 |
| Schettini F, Giudici F, Generali D. (2023) Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives. Heliyon. 10: e23367 |
| Zattarin E, Mariani L, Menichetti A, et al. (2023) Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors. Therapeutic Advances in Medical Oncology. 15: 17588359231204857 |
| Dri A, Arpino G, Bianchini G, et al. (2023) Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs). Cancer Treatment Reviews. 123: 102672 |
| Cazzaniga ME, Ademuyiwa F, Petit T, et al. (2023) Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer. Jnci Cancer Spectrum |
| Favero D, Generali D, Schettini F. (2023) Editorial: Diagnostic, prognostic and predictive factors of response in the era of precision oncology in breast cancer. Frontiers in Oncology. 13: 1337315 |
| Conte B, Boni L, Bisagni G, et al. (2023) SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Dieci MV, Conte PP, Bisagni PG, et al. (2023) Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer. Journal of the National Cancer Institute |
| Ferro A, Generali D, Caffo O, et al. (2023) Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? Seminars in Oncology. 50: 90-101 |
| Zambelli A, Cazzaniga M, La Verde N, et al. (2023) A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy. Breast (Edinburgh, Scotland). 71: 113-121 |